1.	AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO22224, 2009-011400-33, NCT00976911
2.	Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 70 and over Sponsor: Other Protocol IDs: GERICO11/PACS10, 2011-004744-22, UC-0103/1102, NCT01564056
3.	The Myocet/Lapatinib Study Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ICORG 10-03, NCT01495884
4.	Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: Over 18 Sponsor: Other Protocol IDs: MYCA (GINECO-OV220), 2012-001999-10, NCT01705158
5.	Rituximab, Cyclophosphamide, Vincristine Sulfate, and Prednisone With or Without Liposome-Encapsulated Doxorubicin Citrate in Treating Older Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 70 and over Sponsor: Other Protocol IDs: CDR0000636032, IB-FRAIL06, INCA-RECF0892, IB-2008-25, EUDRACT-2008-001506-16, FRAIL 06, NCT00911183
6.	Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: ADOPEH-LINFMYO-2007, NCT00849355
7.	Phase II Study of Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Patients With Primary Advanced or Metastatic Recurrent Endometrial Carcinoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MUI-AGO-15, MUI-AGO-15, EUDRACT-2007-004060-40, EU-21027, NCT01100359
8.	Phase II Randomized Study of Liposome-Encapsulated Doxorubicin Citrate With Versus Without Gemcitabine Hydrochloride in Patients With Platinum-Refractory or Platinum-Resistant Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MUI-AGO-10, MUI-AGO-10, EUDRACT-2008-008746-20, EU-21028, NCT01100372
9.	Myocet Plus Endoxan for Older Patients With Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 70 and over Sponsor: Other Protocol IDs: CT/08.32, NCT01120171
10.	First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: VICC BMT 1020, NCT01215344
11.	Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: AVANTHER, NCT01321775
12.	A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ABCSG 32, 2010-023324-25, NCT01367028
13.	A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IIL - HD0803, EudraCT Number 2009-013839-37, NCT01523847
14.	Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 74 Sponsor: Other Protocol IDs: SOLTI-1002, 2012-001201-24, NCT01669239
15.	History of the KSHV Inflammatory Cytokine Syndrome (KICS) Phase: No phase specified Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110220, 11-C-0220, NCT01419561